Advances in the treatment strategies in hypertension: present and future
P Verdecchia, C Cavallini, F Angeli - Journal of cardiovascular …, 2022 - mdpi.com
Hypertension is the most frequent chronic and non-communicable disease all over the
world, with about 1.5 billion affected individuals worldwide. Its impact is currently growing …
world, with about 1.5 billion affected individuals worldwide. Its impact is currently growing …
Novel pharmacological approaches in the treatment of hypertension: a focus on RNA-based therapeutics
ML Addison, P Ranasinghe, DJ Webb - Hypertension, 2023 - Am Heart Assoc
Hypertension remains the leading cause of cardiovascular disease and premature death
globally, affecting half of US adults. A high proportion of hypertensive patients exhibit …
globally, affecting half of US adults. A high proportion of hypertensive patients exhibit …
Small Interfering RNA Therapeutics in Hypertension: A Viewpoint on Vasopressor and Vasopressor‐Sparing Strategies for Counteracting Blood Pressure Lowering by …
P Ranasinghe, ML Addison… - Journal of the American …, 2022 - Am Heart Assoc
Hypertension is an extremely common noncom-municable condition affecting an estimated
1.3 billion adults (aged 30–79 years) worldwide and with a prevalence that has doubled …
1.3 billion adults (aged 30–79 years) worldwide and with a prevalence that has doubled …
Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension
ML Addison, P Ranasinghe… - Expert Review of Clinical …, 2023 - Taylor & Francis
Introduction Hypertension is the main global risk factor for cardiovascular disease. Despite
this, less than half of treated hypertensive patients are controlled. One reason for this is …
this, less than half of treated hypertensive patients are controlled. One reason for this is …
Are high-or low-dose SGLT2 inhibitors associated with cardiovascular and respiratory adverse events? A meta-analysis
HT Zou, GH Yang, YJ Cai, H Chen… - Journal of …, 2022 - journals.lww.com
The association between high-dose or low-dose sodium-glucose cotransporter 2 (SGLT2)
inhibitors and various cardiovascular and respiratory serious adverse events (SAE) is …
inhibitors and various cardiovascular and respiratory serious adverse events (SAE) is …
Association between SGLT2is and cardiovascular and respiratory diseases: A meta-analysis of large trials
DG Yin, M Qiu, XY Duan - Frontiers in Pharmacology, 2021 - frontiersin.org
The association between sodium-glucose cotransporter 2 inhibitors (SGLT2is) and various
cardiovascular and respiratory diseases is unestablished. This meta-analysis aimed to …
cardiovascular and respiratory diseases is unestablished. This meta-analysis aimed to …
[PDF][PDF] Lactobacillus and Allobaculum mediates the improvement of vascular endothelial dysfunction during hypertension with TaohongSiwu decoction combined with …
T Liu, X Li, C Zhang, L Zhao, X Li, Y Yu, Y Zhou, Y Xue - Heliyon, 2023 - cell.com
Background Previous study confirmed that both TaohongSiwu decoction (THSWD) and
Dubosiella newyorkensis improved hypertension-induced endothelial dysfunction. However …
Dubosiella newyorkensis improved hypertension-induced endothelial dysfunction. However …
Recent Developments in Drug Targets and Combination Therapy for the Clinical Management of Hypertension
PK Niranjan, S Bahadur - Cardiovascular & Haematological …, 2023 - ingentaconnect.com
Raised blood pressure is the most common complication worldwide that may lead to
atherosclerosis and ischemic heart disease. Unhealthy lifestyles, smoking, alcohol …
atherosclerosis and ischemic heart disease. Unhealthy lifestyles, smoking, alcohol …
The association of ideal cardiovascular health metrics and incident hypertension among an urban population of Iran: a decade follow-up in Tehran Lipid and Glucose …
We aimed to determine the association between ideal cardiovascular health metrics
(ICVHM) and the incidence of hypertension among Iranian adults. The study population …
(ICVHM) and the incidence of hypertension among Iranian adults. The study population …
Resistant Hypertension: Disease Burden and Emerging Treatment Options
JM Flack, MG Buhnerkempe, KT Moore - Current Hypertension Reports, 2024 - Springer
Abstract Purpose of Review To define resistant hypertension (RHT), review its
pathophysiology and disease burden, identify barriers to effective hypertension …
pathophysiology and disease burden, identify barriers to effective hypertension …